Floatz logo

Vinorelbine

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter

National Cancer Institute (NCI)Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Beijing Biotech
Phase 2BB
TRASTUZUMAB
National Cancer Institute (NCI)
Phase 2BB
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 2B
Gefetinib
National Cancer Institute (NCI)
Phase 2B
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2B

View all 12 →

Same molecule, other indications

Vinorelbine is also rated in:

HER2 positive breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Recurrent Breast CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →